Single-arm trials for domestic oncology drug approvals in China
Cancer Biol Med
.
2023 Nov 27;20(11):799-805.
doi: 10.20892/j.issn.2095-3941.2023.0360.
Authors
Hong Zhang
#
1
,
Sen Liu
#
2
,
Chenghao Ge
2
,
Xiaozhen Liu
2
,
Yang Liu
2
,
Chen Yin
2
,
Yi Li
2
,
Jing An
2
,
Zhongtian Yan
2
,
Xiaoyuan Chen
2
3
Affiliations
1
Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China.
2
Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
3
Office of Clinical Trial Institute, Beijing Tsinghua Changgung Hospital, Beijing 102218, China.
#
Contributed equally.
PMID:
38013490
PMCID:
PMC10690876
DOI:
10.20892/j.issn.2095-3941.2023.0360
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
Antineoplastic Agents* / therapeutic use
China
Drug Approval*
Humans
Medical Oncology
Substances
Antineoplastic Agents
Grants and funding
2023-Y-Y-002/China Society for Drug Regulation